Rapport Therapeutics (RAPP) Gains from Investment Securities (2023 - 2025)

Rapport Therapeutics (RAPP) has 3 years of Gains from Investment Securities data on file, last reported at $6.3 million in Q3 2025.

• Gains from Investment Securities for Q3 2025 came in at $6.3 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was $6.3 million (changed N/A YoY), and the FY2025 annual result was $6.3 million, up 6483.75% from the prior year.
• Gains from Investment Securities climbed to $6.3 million in Q3 2025 per RAPP's latest filing, from $6.1 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $6.3 million in Q3 2025 and troughed at $95500.0 in Q4 2024.
• A 3-year average of $3.1 million and a median of $1.6 million in 2025 frame the typical range for Gains from Investment Securities.
• On a YoY basis, Gains from Investment Securities climbed as much as 93.06% in 2024 and fell as far as 93.06% in 2024.
• A 3-year view of Gains from Investment Securities shows it stood at $1.4 million in 2023, then sank by 93.06% to $95500.0 in 2024, then jumped by 6493.37% to $6.3 million in 2025.
• Business Quant data shows RAPP's Gains from Investment Securities at $6.3 million in Q3 2025, $6.1 million in Q2 2025, and $1.6 million in Q1 2025.